Induction of death receptor 5 and suppression of survivin contribute to sensitization of TRAIL-induced cytotoxicity by quercetin in non-small cell lung cancer cells

被引:96
作者
Chen, Wenshu
Wang, Xia
Zhuang, Jianguo
Zhang, Lin
Lin, Yong
机构
[1] Lovelace Resp Res Inst, Mol Biol & Lung Canc Program, Albuquerque, NM 87108 USA
[2] Sichuan Univ, Lab Mol & Translat Med, W China Univ Hosp 2, Chengdu 610041, Peoples R China
关键词
D O I
10.1093/carcin/bgm133
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The natural flavonoid quercetin has been suggested by epidemiological studies to have preventive activity against lung cancer; however, the mechanism of which has not been well elucidated. In this report, we demonstrate that quercetin significantly enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cytotoxicity in non-small cell lung cancer (NSCLC) cells. Quercetin increased expression of death receptor (DR) 5, whereas it had no effect on that of other components of the death-inducing signaling complex. Conversely, the expression of survivin was potently inhibited by quercetin. We further determined that Protein Kinase C (PKC) is essential for DR5 induction but is dispensable for suppression of survivin expression. In contrast, the blockage of the serine/threonine kinase Akt activity by quercetin is important for inhibition of survivin expression but not induction of DR5. These results suggest the pathways for regulation of DR5 and survivin expression by quercetin are distinct. Importantly, suppression of survivin-sensitized TRAIL-induced cell death and blockage of DR5 expression suppressed the synergistic cytotoxicity induced by quercetin and TRAIL co-treatment. On the whole, our data show that quercetin sensitizes TRAIL-induced cytotoxicity in lung cancer cells through two independent pathways: induction of DR5 and suppression of survivin expression, which may underlie the mechanism of the lung cancer preventive activity of quercetin. The potentiation of TRAIL-induced NSCLC cell death could be implicated in lung cancer therapy and prevention.
引用
收藏
页码:2114 / 2121
页数:8
相关论文
共 45 条
[1]   Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation [J].
Belyanskaya, LL ;
Hopkins-Donaldson, S ;
Kurtz, S ;
Simoes-Wüst, AP ;
Yousefi, S ;
Simon, HU ;
Stahel, R ;
Zangemeister-Wittke, U .
INTERNATIONAL JOURNAL OF CANCER, 2005, 117 (05) :755-763
[2]   Dietary agents in cancer prevention: flavonoids and isoflavonoids [J].
Birt, DF ;
Hendrich, S ;
Wang, WQ .
PHARMACOLOGY & THERAPEUTICS, 2001, 90 (2-3) :157-177
[3]   Induction of apoptosis by quercetin: different response of human chronic myeloid (K562) and acute lymphoblastic (HSB-2) leukemia cells [J].
Brisdelli, Fabrizia ;
Coccia, Cristina ;
Cinque, Benedetta ;
Cifone, Maria Grazia ;
Bozzi, Argante .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 2007, 296 (1-2) :137-149
[4]   Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis [J].
Chawla-Sarkar, M ;
Bae, SI ;
Reu, FJ ;
Jacobs, BS ;
Lindner, DJ ;
Borden, EC .
CELL DEATH AND DIFFERENTIATION, 2004, 11 (08) :915-923
[5]   Activation of conventional PKC isoforms increases expression of the pro-apoptotic protein bad and TRAIL receptors [J].
Farrow, B ;
Thomas, RP ;
Wang, XF ;
Evers, BM .
JOURNAL OF GASTROINTESTINAL CANCER, 2002, 32 (2-3) :63-72
[6]   Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5 [J].
Frese, S ;
Frese-Schaper, M ;
Andres, AC ;
Miescher, D ;
Zumkehr, B ;
Schmid, RA .
CANCER RESEARCH, 2006, 66 (11) :5867-5874
[7]   Protein kinase C and prostate carcinogenesis: Targeting the cell cycle and apoptotic mechanisms [J].
Gavrielides, MV ;
Frijhoff, AF ;
Conti, CJ ;
Kazanietz, MG .
CURRENT DRUG TARGETS, 2004, 5 (05) :431-443
[8]   The two faces of NFκB in cell survival responses [J].
Graham, B ;
Gibson, SB .
CELL CYCLE, 2005, 4 (10) :1342-1345
[9]   Dihydroflavonol BB-1, an extract of natural plant Blumea balsamifera, abrogates TRAIL resistance in leukemia cells [J].
Hasegawa, H ;
Yamada, Y ;
Komiyama, K ;
Hayashi, M ;
Ishibashi, M ;
Yoshida, T ;
Sakai, T ;
Koyano, T ;
Kam, TS ;
Murata, K ;
Sugahara, K ;
Tsuruda, K ;
Akamatsu, N ;
Tsukasaki, K ;
Masuda, M ;
Takasu, N ;
Kamihira, S .
BLOOD, 2006, 107 (02) :679-688
[10]  
JEMAL A, 2005, CANCER, V97, P3133